Locked Into One Brand's Pancreas

Automated insulin delivery (AID) systems combine continuous glucose monitors (CGMs), insulin pumps, and control algorithms into a closed loop — but each system is locked into a single manufacturer's ecosystem. A patient cannot pair a CGM from one company with a pump from another and an algorithm from a third, even when each component is individually FDA-cleared. The FDA created "interoperability designations" (iCGM, ACE pump) intended to enable mix-and-match, but every cleared AID algorithm still works with only one pump manufacturer's hardware. This vendor lock-in limits patient choice, creates supply chain fragility, and blocks third-party algorithm developers who lack pump hardware from entering the market.

Approximately 1.9 million Americans with Type 1 diabetes are candidates for AID systems. Vendor lock-in forces patients to replace their entire system if any single component is recalled, discontinued, or outperformed — and prevents patients from selecting the most accurate CGM alongside their preferred pump. The inability of independent algorithm developers to compete without building pump hardware reduces innovation pressure across the entire ecosystem.

The FDA's iCGM and ACE pump designations were designed to create interoperable component classes, but they have not produced system-level interoperability because no standardized communication protocol, data format, or safety verification framework exists for cross-manufacturer component interaction. Tidepool Loop, an open-source algorithm, received FDA clearance in 2023 but remains commercially unavailable because no pump manufacturer has obtained the separate FDA clearance needed to pair with an alternative controller. The Abbott-Medtronic partnership (August 2024) to integrate their CGM and pump illustrates that interoperability currently requires bilateral commercial agreements rather than open standards. The DIY artificial pancreas community (Loop, OpenAPS, AndroidAPS) has proven that cross-manufacturer interoperability is technically feasible, but these systems operate outside FDA oversight and cannot serve as a regulatory model.

A standardized communication protocol and safety verification framework for AID components — analogous to USB or Bluetooth in consumer electronics — would allow any cleared algorithm to operate on any ACE pump with any iCGM. Solving the combinatorial testing problem (validating N x M component pairings without testing every combination) and establishing clear liability assignment for multi-manufacturer system failures would remove the two deepest structural barriers.

A student team could prototype a middleware layer that translates between the proprietary communication protocols of existing CGMs and pumps, demonstrating feasibility on bench hardware. Alternatively, a team could develop a simulation-based safety verification framework that characterizes algorithm-pump interaction safety without requiring physical testing of every combination. Mapping the current regulatory pathway gaps and proposing a concrete standards roadmap would also be a valuable design-research contribution.